CYBN vs. CMPS, VERV, ALT, IGMS, LXRX, CDMO, SLRN, PGEN, CTNM, and ACIU
Should you be buying Cybin stock or one of its competitors? The main competitors of Cybin include COMPASS Pathways (CMPS), Verve Therapeutics (VERV), Altimmune (ALT), IGM Biosciences (IGMS), Lexicon Pharmaceuticals (LXRX), Avid Bioservices (CDMO), Acelyrin (SLRN), Precigen (PGEN), Contineum Therapeutics (CTNM), and AC Immune (ACIU). These companies are all part of the "pharmaceutical preparations" industry.
Cybin (NYSE:CYBN) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
COMPASS Pathways is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways received 49 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 76.92% of users gave COMPASS Pathways an outperform vote.
Cybin currently has a consensus price target of $5.00, suggesting a potential upside of 1,628.91%. COMPASS Pathways has a consensus price target of $47.40, suggesting a potential upside of 611.71%. Given Cybin's higher probable upside, equities analysts plainly believe Cybin is more favorable than COMPASS Pathways.
17.9% of Cybin shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, COMPASS Pathways had 3 more articles in the media than Cybin. MarketBeat recorded 4 mentions for COMPASS Pathways and 1 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat COMPASS Pathways' score of 0.22 indicating that Cybin is being referred to more favorably in the media.
COMPASS Pathways' return on equity of -57.24% beat Cybin's return on equity.
Cybin has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500.
Summary
Cybin and COMPASS Pathways tied by winning 7 of the 14 factors compared between the two stocks.
Get Cybin News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
